Clinical trial
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
NCT00336843 · Asan Medical Center, Other · Completed
Key facts
| NCT number | NCT00336843 |
|---|---|
| Title | Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma |
| Official title | Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy of BuCyE and Autologous Stem Cell Transplantation in Patients With B-cell Non-Hodgkin's Lymphoma - an Open-labeled Phase II Study |
| Lead sponsor | Asan Medical Center, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Zevalin-BuCyE |
| Enrollment | 19 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Jun 14, 2006 |
| Last update posted | Feb 17, 2016 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: